Steven W. Fleming
Steven W. Fleming has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Brooks Wright
Emergency Medicine, MountainView Hospital, Las Vegas, NV, USA
1 shared publicationEmily Bouso Raley
North Louisiana Criminalistics Laboratory, Shreveport, LA, USA
1 shared publicationHayden Maag
Emergency Medicine, MountainView Hospital, Hca Healthcare, Las Vegas, NV, USA
1 shared publicationJoshua DeBord
North Louisiana Criminalistics Laboratory, Shreveport, LA, USA
1 shared publication- Kerry Anne Rambaran
UCSD Medical Center East Campus San Diego California USA
1 shared publication - Kristina Domanski
Department of Emergency Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, Nevada
1 shared publication
Latest Publications
- 28 November 2021
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- Vol. 54 (4) , 319-323
A Psychonaut’s Experience of Intoxication with Multiple Classes of Drugs Including Novel Psychoactive Substance 2-fluorodeschloroketamine: Case Report and Urinary Analysis
Novel psychoactive substances have emerged as drugs of abuse. 2-Fluorodeschloroketamine (2-FDCK) is a ketamine derivative that can be purchased online for as little as $12 per gram. We report the case of a patient with a history of polysubstance use presenting after insufflation of 2-FDCK, with subsequent confirmation of metabolites in the patient’s urine. A 28-year-old man presented to the Emergency Department in a dissociated state. He recovered well with supportive care, and described during interview his experience of substance use including the novel psychoactive substance 2-FDCK. A urine sample was sent for analysis and 2-FDCK metabolites were isolated. This case is concerning because 2-FDCK is a relatively new agent that has not yet been reported in the United States. It is easy to obtain over the internet and has significant abuse potential.
- 28 November 2021
- Published by Taylor & Francis in Journal of Psychoactive Drugs
- Vol. 54 (4) , 319-323
A Psychonaut’s Experience of Intoxication with Multiple Classes of Drugs Including Novel Psychoactive Substance 2-fluorodeschloroketamine: Case Report and Urinary Analysis
Novel psychoactive substances have emerged as drugs of abuse. 2-Fluorodeschloroketamine (2-FDCK) is a ketamine derivative that can be purchased online for as little as $12 per gram. We report the case of a patient with a history of polysubstance use presenting after insufflation of 2-FDCK, with subsequent confirmation of metabolites in the patient’s urine. A 28-year-old man presented to the Emergency Department in a dissociated state. He recovered well with supportive care, and described during interview his experience of substance use including the novel psychoactive substance 2-FDCK. A urine sample was sent for analysis and 2-FDCK metabolites were isolated. This case is concerning because 2-FDCK is a relatively new agent that has not yet been reported in the United States. It is easy to obtain over the internet and has significant abuse potential.
- 21 May 2018
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 31 (3) , 303-306
AH-7921: A review of previously published reports
AH-7921 is a synthetic opioid that was developed in the early 1970s. It has resulted in several fatal and nonfatal intoxications, despite not having approval from the US Food and Drug Administration. To date, AH-7921 is listed as a schedule I drug, and there have been no clinical trials exploring the safety of AH-7921. Herein, we provide an analysis of existing case reports available in the literature regarding AH-7921. We searched PubMed, Scopus, Web of Science, and EBSCO for articles (up until December 2017) using the terms “AH-7921” and “AH7921.” In total, 48 articles were identified, and 5 articles were included in our review. A total of 14 cases were found, of which 13 resulted in fatalities. The oral route of administration was reported in two cases, and most cases reported use of concomitant pharmaceutical agents. Pulmonary edema was the most common finding postmortem among deceased cases, with nine of the cases having heavier lungs. Overall, fatalities occurred with low and high concentrations of AH-7921 in the femoral blood. We strongly encourage toxicology screenings for this novel opioid to be included when an overdose of an opioid of unknown nature is suggested.
- 21 May 2018
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 31 (3) , 303-306
AH-7921: A review of previously published reports
AH-7921 is a synthetic opioid that was developed in the early 1970s. It has resulted in several fatal and nonfatal intoxications, despite not having approval from the US Food and Drug Administration. To date, AH-7921 is listed as a schedule I drug, and there have been no clinical trials exploring the safety of AH-7921. Herein, we provide an analysis of existing case reports available in the literature regarding AH-7921. We searched PubMed, Scopus, Web of Science, and EBSCO for articles (up until December 2017) using the terms “AH-7921” and “AH7921.” In total, 48 articles were identified, and 5 articles were included in our review. A total of 14 cases were found, of which 13 resulted in fatalities. The oral route of administration was reported in two cases, and most cases reported use of concomitant pharmaceutical agents. Pulmonary edema was the most common finding postmortem among deceased cases, with nine of the cases having heavier lungs. Overall, fatalities occurred with low and high concentrations of AH-7921 in the femoral blood. We strongly encourage toxicology screenings for this novel opioid to be included when an overdose of an opioid of unknown nature is suggested.